In further embodiments, the auris formulation or composition contains a viscosity enhancing agent or viscosity modulating agent sufficient to provide a viscosity of about 2 cP to about 250,000 cP, about 2 cP to about 100,000 cP, about 2 cP to about 50,000 cP, about 2 cP to about 25,000 cP, about 2 cP to about 10,000 cP, about 2 cP to about 5,000 cP, about 2 cP to about 1,000 cP, about 2 cP to about 500 cP, about 2 cP to about 250 cP, about 2 cP to about 100 cP, about 2 cP to about 90 cP, about 2 cP to about 80 cP, about 2 cP to about 70 cP, about 2 cP to about 60 cP, about 2 cP to about 50 cP, about 2 cP to about 40 cP, about 2 cP to about 30 cP, about 2 cP to about 20 cP, or about 2 cP to about 10 cP
The first two exons are mutually exclusive for their use, and each exon has multiple transcription initiation sites, therefore generating different 5-UTRs and N-terminal signal sequences
Supplementary Table 2 (download XLSX CRISPR screen dataset
The relevance of GLS1 in GBM cells survival was demonstrated in GBM cells transfected with anti- GLS1 siRNAs, by the significant reduction in GLS1 expression confirmed at mRNA and protein levels (Fig
Some peptide effects show in weeks, but many require months of consistent use for noticeable change
